Description: Aditx Therapeutics, Inc., is developing technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system.
Home Page: www.aditxt.com
ADTX Technical Analysis
737 North Fifth Street
Richmond,
VA
23219
United States
Phone:
909 488 0844
Officers
| Name | Title |
|---|---|
| Mr. Amro A. Albanna | Co-Founder, Chairman & CEO |
| Ms. Corinne D. Pankovcin CPA, CPA, M.B.A. | Pres |
| Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D. | Co-Founder, Chief Innovation Officer, Sec. & Director |
| Mr. Thomas J. Farley CPA | Chief Financial Officer |
| Ms. Rowena Albanna | Chief Operating Officer |
| Mr. Matthew M. Shatzkes | Chief Legal Officer & Gen. Counsel |
| Ms. Jennifer Lee | Director of HR |
| Dr. Dolly B. Tyan Ph.D. | Sr. VP of Clinical Devel. ? Transplantation |
| Mr. Ge Chen M.D., M.S. | Sr. VP of Preclinical Research & Discovery |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0.3707 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5245 |
| Price-to-Sales TTM: | 7.9501 |
| IPO Date: | 2020-06-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 58 |